Clinical Trials
The Parkinson's Progression Markers Initiative (PPMI) 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort
Lead Researcher: Ruth Schneider
The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational,
multi-center natural history study to assess progression of clinical features, digital
outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression
in study participants with manifest PD, prodromal PD, and healthy controls.
The overall goal of the study is to identify markers of disease progression for use in
clinical trials of therapies to reduce progression of PD disability.
View Study Details
Publications
Journal Articles
10/2022
Jensen-Roberts S, Myers TL, Auinger P, Cannon P, Rowbotham HM, Coker D, Chanoff E, Soto J, Pawlik M, Amodeo K, Sharma S, Valdovinos B, Wilson R, Sarkar A, McDermott MP, Alcalay RN, Biglan K, Kinel D, Tanner C, Winter-Evans R, Augustine EF, Holloway RG, Dorsey ER, Schneider RB. "A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease: Baseline Results." Neurology. Genetics.. 2022 Oct; 8(5):e200008. Epub 2022 Aug 11.
9/21/2022
Liu Y, Zhang G, Tarolli CG, Hristov R, Jensen-Roberts S, Waddell EM, Myers TL, Pawlik ME, Soto JM, Wilson RM, Yang Y, Nordahl T, Lizarraga KJ, Adams JL, Schneider RB, Kieburtz K, Ellis T, Dorsey ER, Katabi D. "Monitoring gait at home with radio waves in Parkinson's disease: A marker of severity, progression, and medication response." Science translational medicine.. 2022 Sep 21; 14(663):eadc9669. Epub 2022 Sep 21.
7/10/2022
Wills AM, Golbe LI, Lang AE, Xie T, Dale ML, Espay A, Tartaglia MC, Fox SH, Parashos SA, McFarland NR, Schneider RB, Rodriguez-Porcel F, Gunzler SA, Pantelyat A. "Recommendations for Virtual Administration of the PSP Rating Scale." Movement disorders : official journal of the Movement Disorder Society.. 2022 Jul 10; Epub 2022 Jul 10.
VIEW ALL PUBLICATIONS